Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureE Hindriks, Zandvliet MMJM, Sijts AJAM, F Broere
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients
10.1016/j.heliyon.2021.e06210 · 2021
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas
10.1354/vp.44-6-823 · 2007
Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma
10.1007/s00262-005-0025-6 · 2006
NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy
10.1002/ctm2.70020 · 2024
Predictors of mucosal melanoma survival in a population-based setting
10.1016/j.jaad.2018.09.054 · 2019
Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity
10.1158/0008-5472.can-12-3366 · 2013
Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours
10.1016/j.vetimm.2020.110142 · 2020
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
10.4049/jimmunol.172.5.3289 · 2004
A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy × 6 radiotherapy protocol
10.1111/vco.12815 · 2022
Prognosis of acral melanoma: A series of 281 patients
10.1245/s10434-013-3089-0 · 2013
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center
10.1016/j.vaccine.2005.08.027 · 2006
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial
2003
Autologous hybrid cell fusion vaccine in a spontaneous intermediate model of breast carcinoma
10.4142/jvs.2019.20.e48 · 2019
Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001–2012)
10.2460/javma.245.4.401 · 2014
Tumor immune microenvironment and its clinicopathological and prognostic associations in canine splenic hemangiosarcoma
10.3390/ani14081224 · 2024
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024
Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs
10.1016/j.vetimm.2023.110691 · 2024
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
10.1038/s41586-019-1914-8 · 2020
Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: Comparison of two vaccination protocols
10.1080/01652176.2025.2473717 · 2025
Intratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumors
10.1016/j.vetimm.2016.06.006 · 2016
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate
10.1016/j.vetimm.2020.110169 · 2021
Expression of MAGE-A restricted to testis and ovary or to various cancers in dogs
10.1016/j.vetimm.2013.01.012 · 2013
Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas
10.1354/vp.40-6-713 · 2003
Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
10.1371/journal.pone.0235518 · 2020
PD-1 expression by canine T cells and functional effects of PD-1 blockade
10.1111/vco.12294 · 2017
Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model
10.21873/anticanres.13275 · 2019
A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients
10.1158/2326-6066.cir-18-0500 · 2019
Development of effective tumor immunotherapy using a novel dendritic cell–targeting Toll-like receptor ligand
10.1371/journal.pone.0188738 · 2017
Deregulation of VEGFR-2 and PDGFR expression and microvascular density in a triple-negative model of canine malignant mammary tumors with lymph node or lung metastasis
10.3390/vetsci6010003 · 2019
Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
10.1016/j.tranon.2021.101205 · 2021
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
2002
Unresolved referenced work
Kept as external metadata until matched
M1 and M2 macrophages’ clinicopathological significance in cutaneous melanoma
10.1097/cmr.0000000000000352 · 2017
The testis in immune privilege
10.1111/j.1600-065x.2006.00438.x · 2006
Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up
10.1038/cgt.2012.72 · 2012
Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma
10.1111/jvim.15852 · 2020
Cancer registration in dogs and cats: A narrative review of history, current status, and standardization efforts
10.1016/j.rvsc.2025.105673 · 2025
Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
2017
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
10.1084/jem.192.7.1027 · 2000
Prognostic value of tumor-infiltrating lymphocytes in melanoma: A systematic review and meta-analysis
10.1080/2162402x.2019.1593806 · 2019
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
10.1136/jitc-2023-008611 · doi-reference
Real-world efficacy and safety of anti-PD-1 antibody plus apatinib and temozolomide for advanced acral melanoma
10.2147/cmar.s520937 · doi-reference
Recent advances in therapeutic cancer vaccines
10.1038/s41568-025-00820-z · doi-reference
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
10.1080/19420862.2023.2287250 · doi-reference
Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma
10.1016/j.vetimm.2024.110716 · doi-reference
CD204+ tumor-associated macrophages are associated with clinical outcome in canine pulmonary adenocarcinoma and transitional cell carcinoma
10.1016/j.tvjl.2023.105992 · doi-reference
Intratumoral T-lymphocyte subsets in canine oral melanoma and their association with clinical and histopathological parameters
10.1177/0300985821999321 · doi-reference
Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs
10.1016/j.vetimm.2016.10.011 · doi-reference
Genomic features of exceptional response in vemurafenib cobimetinib–treated patients with BRAFV600-mutated metastatic melanoma
10.1158/1078-0432.ccr-18-0720 · doi-reference
Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma
10.1200/jco.20.00902 · doi-reference
Immunotherapeutic allogeneic dendritic cell and autologous tumor cell fusion vaccine alone or combined with radiotherapy in canine oral malignant melanoma is safe and potentially effective
10.3389/fvets.2024.1397518 · doi-reference
The role of angiogenesis in melanoma: Clinical treatments and future expectations
10.3389/fphar.2022.1028647 · doi-reference
Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study
10.1111/vco.12332 · doi-reference
Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma
10.1158/1078-0432.ccr-18-2652 · doi-reference
Estimation of clinical trial success rates and related parameters
10.1093/biostatistics/kxx069 · doi-reference
Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma
10.1097/cji.0b013e31829d8a1b · doi-reference
Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors
10.1111/j.1740-8261.2004.04045.x · doi-reference
Streptavidin: A novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines
10.1158/2326-6066.cir-13-0157 · doi-reference
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study
10.1016/s0140-6736(23)02268-7 · doi-reference
Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors
10.1517/14728222.2015.1068759 · doi-reference
Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK
10.1111/jsap.12613 · doi-reference
Comparative expression pathway analysis of human and canine mammary tumors
10.1186/1471-2164-10-135 · doi-reference
Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages
10.1172/jci80006 · doi-reference
Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma
10.1111/j.1939-1676.2007.tb02936.x · doi-reference
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial
10.1158/2326-6066.cir-13-0089 · doi-reference
A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma
10.1292/jvms.15-0510 · doi-reference
Receptor tyrosine kinases in osteosarcoma treatment: Which is the key target?
10.3389/fonc.2020.01642 · doi-reference
A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma
10.1016/j.ymthe.2023.06.004 · doi-reference
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
10.1002/cncr.31734 · doi-reference
A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: A case report and in vitro analysis
10.1186/s12917-021-02864-3 · doi-reference
Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells
10.1016/j.tvjl.2006.11.005 · doi-reference
Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma
10.1371/journal.pone.0201222 · doi-reference
Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma
10.1053/jcpa.2002.0576 · doi-reference
Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort
10.1245/s10434-022-11478-4 · doi-reference
PD-1, PD-L1, and PD-L2 gene expression and tumor infiltrating lymphocytes in canine melanoma
10.1177/03009858211011939 · doi-reference
Association between metastatic melanoma response to checkpoint inhibitor therapy and tumor-infiltrating lymphocyte classification on primary cutaneous melanoma biopsies
10.1001/jamadermatol.2022.4959 · doi-reference
Long-term relative survival in uveal melanoma: A systematic review and meta-analysis
10.1038/s43856-022-00082-y · doi-reference
A preliminary study of the cross-reactivity of canine MAGE-A with hominid monoclonal antibody 6C1 in canine mammary gland tumors: An attractive target for cancer diagnostic, prognostic and immunotherapeutic development in dogs
10.3390/vetsci7030109 · doi-reference
Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
10.1200/jco.2009.23.7537 · doi-reference
Prospective study of successful autologous dendritic cell therapy in dogs with splenic stage II hemangiosarcoma
10.1016/j.tvjl.2024.106196 · doi-reference